Evotec Receives $ 23.8 Million Treasury Board Grant

Evotec SE has entered into a five-year partnership with the Bill & Melinda Gates Foundation to uncover new treatment regimens to better control TB, a serious threat to health and one of the leading causes of cancer. deaths by infectious diseases worldwide.

Evotec will receive a grant of approximately $ 23.8 million over five years to generate standardized, high quality preclinical data to support the selection and development of new treatment regimens.

The current standard TB treatment regimen consists of a minimum of 6 months of treatment with four drugs administered under direct observation, but treatment is much longer when TB is drug-resistant. The new regimen should be safer, shorter in duration and more effective than the current standard treatment.

Dr. Werner Lanthaler, President and CEO of Evotec, said, "We are honored to partner with the Bill & Melinda Gates Foundation to fight TB, one of the world's deadliest infectious diseases. we are convinced that this combined international effort is the best possible starting point to bring huge benefits to the large number of TB patients around the world. "